Aldeyra Therapeutics
ALDX
38 hedge funds and large institutions have $66.5M invested in Aldeyra Therapeutics in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 6 closing their positions.
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
9% more funds holding
Funds holding: 35 → 38 (+3)
1.94% more ownership
Funds ownership: 49.2% → 51.14% (+1.9%)
0% more capital invested
Capital invested by funds: $66.4M → $66.5M (+$95K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.5M |
| 2 |
Millennium Management
New York
|
+$1.12M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$1.08M |
| 4 |
6CM
683 Capital Management
New York
|
+$524K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$335K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$375K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$365K |
| 3 |
EMG
Ellington Management Group
Old Greenwich,
Connecticut
|
-$168K |
| 4 |
Squarepoint
New York
|
-$159K |
| 5 |
Renaissance Technologies
New York
|
-$152K |
ALDX Hedge Fund Activity: Q4 2017 in Review
38 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q4 2017, worth a combined $66.5M — up 0.14% from $66.4M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ALDX positions and 6 closed out — a net gain of 3 holders — while 13 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.5M. The largest seller was Adage Capital Partners, cutting an estimated $375K.
- 38 institutional investors held Aldeyra Therapeutics (ALDX) as of Q4 2017, up from 35 in Q3 2017.
- Funds reported $66.5M of Aldeyra Therapeutics stock for Q4 2017, up 0.14% quarter-over-quarter.
- 9 funds opened new Aldeyra Therapeutics positions in Q4 2017 and 6 closed out, a net change of +3 holders.
- The largest Aldeyra Therapeutics buyer in Q4 2017 was Vanguard Group, an estimated $1.5M added.
- The largest Aldeyra Therapeutics seller in Q4 2017 was Adage Capital Partners, an estimated $375K sold.
Based on aggregated 13F filings for Q4 2017.